



Announcement Summary

Entity name

ALGORAE PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Monday April 22, 2024

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

The purpose of this Appendix 2A is to quote 25,000,000 performance rights which vested and converted into shares (subject of the Appendix 3G dated 28 December 2023)

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
1AI	ORDINARY FULLY PAID	25,000,000	28/12/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ALGORAE PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

104028042

1.3 ASX issuer code

1AI

1.4 The announcement is

New announcement

1.5 Date of this announcement

22/4/2024



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The purpose of this Appendix 2A is to quote 25,000,000 performance rights which vested and converted into shares (subject of the Appendix 3G dated 28 December 2023)

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

1AI : ORDINARY FULLY PAID

Issue date

28/12/2023

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

25,000,000

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

The securities were issued on vesting of the 2nd tranche of performance rights, following the satisfaction of milestones detailed in ASX announcements dated 26 July 2023 and 23 November 2023.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

The securities were issued on vesting of performance rights held by KMP. Refer Appendix 3G lodged on 28 December 2023.



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
1AI : ORDINARY FULLY PAID	1,686,352,445
1AIO : OPTION EXPIRING 31-MAR-2026	306,403,577

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
1AIAN : OPTION EXPIRING 01-SEP-2024 EX \$0.132	1,000,000
1AIAS : PERFORMANCE RIGHTS	10,000,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

9